Hydroxyzine Pamoate Should NOT Be Used to Treat Palpitations
Hydroxyzine pamoate is contraindicated for treating palpitations and may actually cause or worsen cardiac arrhythmias, including supraventricular tachycardia, QT prolongation, and torsade de pointes. This first-generation antihistamine has well-documented proarrhythmic effects that make it inappropriate for cardiac symptom management.
Why Hydroxyzine Is Dangerous for Palpitations
Direct Cardiac Toxicity
Hydroxyzine causes concentration-dependent inhibition of cardiac ion channels, particularly hERG potassium channels, leading to QT prolongation 1. This mechanism directly increases arrhythmia risk rather than treating it. The FDA drug label confirms that overdosage manifests as hypersedation, convulsions, and cardiovascular effects requiring vasopressor support 2.
Documented Arrhythmogenic Cases
Multiple case reports demonstrate hydroxyzine's ability to induce supraventricular tachycardia and torsade de pointes:
- A 9-year-old developed SVT with heart rate of 250/minute on therapeutic doses, requiring IV verapamil for cardioversion 3
- An 82-year-old developed torsade de pointes after just 12.5 mg during pacemaker implantation 4
- A 58-year-old with an ICD developed refractory torsade de pointes after 50 mg, requiring intubation and sedation for resolution 5
Risk Factors Amplify Danger
Pharmacovigilance data from 1955-2016 identified 59 cases of QT prolongation/torsade de pointes linked to hydroxyzine 1. The greatest combined risk occurs with cardiovascular disorders plus concomitant arrhythmogenic drugs—precisely the population presenting with palpitations who may already have underlying cardiac pathology.
Evidence-Based Treatment for Palpitations
For Supraventricular Tachycardia
If palpitations represent SVT, guideline-directed therapy includes 6:
- Vagal maneuvers as first-line intervention
- IV adenosine for acute termination (6-12 mg rapid push)
- IV beta-blockers (metoprolol, esmolol) or calcium channel blockers (diltiazem, verapamil) for rate control
- Oral beta-blockers for chronic management (Class IIa recommendation)
For Atrial Fibrillation with Rapid Ventricular Response
Rate control should be achieved with 7, 8:
- IV beta-blockers (esmolol or metoprolol) as first-line
- IV diltiazem or verapamil as alternatives
- Target heart rate ≤110 bpm
- Avoid in hypotension, LV dysfunction, or heart failure without careful consideration
For Benign Palpitations
When structural heart disease is excluded 9:
- Beta-blockers remain first-line for symptomatic relief
- Address precipitating factors: caffeine, alcohol, nicotine, hyperthyroidism
- Consider anxiolytic therapy if anxiety-driven, but never hydroxyzine
Critical Pitfalls to Avoid
- Never prescribe hydroxyzine for cardiac symptoms - It causes the very arrhythmias you're trying to prevent
- First-generation antihistamines are inappropriate - The rhinitis guideline explicitly warns about hydroxyzine's sedation, performance impairment, and anticholinergic effects 10, but cardiac toxicity is even more concerning
- Elderly patients face amplified risk - Increased sensitivity to psychomotor impairment and anticholinergic effects 10, plus higher baseline cardiovascular disease burden
- Drug interactions compound danger - Concurrent use with other QT-prolonging agents (antipsychotics, antiarrhythmics, antibiotics) creates multiplicative risk 11, 1
The Bottom Line
If a patient presents with palpitations and you're considering hydroxyzine, you're making a fundamental error in clinical reasoning. Hydroxyzine is an arrhythmogenic agent that belongs nowhere near a patient with cardiac symptoms. Use guideline-directed beta-blockers or calcium channel blockers for rate control, address underlying causes, and refer to cardiology for diagnostic evaluation with ambulatory monitoring when indicated 9.